Literature DB >> 15024382

Pharmacogenetics in the treatment of breast cancer.

V Stearns1, N E Davidson, D A Flockhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15024382     DOI： 10.1038/sj.tpj.6500242

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  15 in total

1.  CD243 gene polymorphism significantly associated with breast cancer susceptibility.

Authors:  Weirong Yao; Rongzeng Yan; Lin Ma; Huiping Wan; Yanmin Yu; Xia Cheng; Yingliang Li
Journal:  Tumour Biol       Date:  2014-05-18

2.  Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients.

Authors:  Anjali Mishra; Richa Chandra; Prateek Kumar Mehrotra; Prachi Bajpai; Deepa Agrawal
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

Review 3.  The role of ovarian ablation in the adjuvant therapy of breast cancer.

Authors:  Sing-Huang Tan; Antonio C Wolff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

4.  Medication use in breast cancer survivors compared to midlife women.

Authors:  Julie L Otte; Todd C Skaar; Jingwei Wu; Menggang Yu; Kristin Ryker; Debra S Burns; Janet S Carpenter
Journal:  Support Care Cancer       Date:  2013-02-10       Impact factor: 3.603

Review 5.  Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

Authors:  Vered Stearns; James M Rae
Journal:  Expert Rev Mol Med       Date:  2008-11-20       Impact factor: 5.600

6.  The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Authors:  Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

7.  Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells.

Authors:  Lancelot McLean; Ubaldo Soto; Keli Agama; Jawad Francis; Randi Jimenez; Yves Pommier; Lawrence Sowers; Eileen Brantley
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

Review 8.  The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment.

Authors:  Sonam Tulsyan; Rama Devi Mittal; Balraj Mittal
Journal:  Pharmgenomics Pers Med       Date:  2016-04-27

9.  Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients.

Authors:  Tatjana I Djukic; Ana R Savic-Radojevic; Tatjana D Pekmezovic; Marija G Matic; Marija S Pljesa-Ercegovac; Vesna M Coric; Tanja M Radic; Sonja R Suvakov; Biljana N Krivic; Dejan P Dragicevic; Tatjana P Simic
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

10.  FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.

Authors:  P Khongkow; U Karunarathna; M Khongkow; C Gong; A R Gomes; E Yagüe; L J Monteiro; M Kongsema; S Zona; E P S Man; J W-H Tsang; R C Coombes; K-J Wu; U-S Khoo; R H Medema; R Freire; E W-F Lam
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.